Case Study: Taking an IVD Reagent Catalog Through COFEPRIS Registration

The catalog was cleared everywhere that mattered except Mexico. A manufacturer of diagnostic agents — reagent panels, assay families, the same tests in several presentations for different laboratory customers — held FDA clearances and CE certificates behind the line, and had a Mexican distributor calling every few weeks to ask when it could start selling.

The plan it arrived with assumed one registration would cover the family — a single filing for a panel that shared a name, a purpose and a technology. Two facts undid that in one conversation. Mexico registers products, not catalogs: each item in the line needed its own registro sanitario. And a foreign manufacturer cannot hold one — the registration has to sit with a Mexican entity. The distributor, helpfully, offered to be that entity.

The offer that would have been hard to undo

The proposal was ordinary and made in good faith. A foreign manufacturer without a Mexican legal entity must appoint a Mexico Registration Holder (MRH) to file dossiers, pay government fees, and stand as the regulatory contact with COFEPRIS — a requirement that sits under the General Health Law and the Regulations of Health Supplies. A distributor volunteering for the role solves the problem in an afternoon.

What made it expensive was a detail in how Mexican registrations are issued. The registro sanitario is granted in the name of the MRH, which makes the holder the legally recognized owner of the authorization. Moving one to a different holder is possible through formal COFEPRIS channels, but cumbersome. Had the sales channel held the catalog's registrations, every later commercial conversation — margins, a second distributor, an exit — would have taken place with the manufacturer's market access sitting on the other side of the table, along with the modifications, renewals and technovigilance filings that run through the holder for the life of each product.

The manufacturer declined, and the roles were separated. Our Mexican entity took the registrations as independent MRH; the distributor stayed a distributor. The two are genuinely different jobs — the MRH holds the registration and answers to COFEPRIS, while importer and distributor handle physical import, customs and labeling compliance — and keeping them apart meant importers and distributors could later be added or changed underneath the registrations without touching the authorizations themselves. That separation is the whole of what our in-country representation model buys.

The classification memo that had gone out of date

The manufacturer arrived with a classification assessment it had no reason to doubt — reasonable, thorough, and written against the wrong edition of the rules.

Mexico classifies devices as Class I (Low Risk), Class I, Class II and Class III, and treats IVDs as their own category classified I, II or III, under rules in Annex II of the Supplement of Medical Devices of the Mexican Pharmacopoeia that draw on IMDRF guidance and the EU directives. Edition 5.0, released in 2023, expanded Annex II to 35 classification rules — and, for a diagnostic-agent line specifically, the IVD rules grew from four to ten.

Re-running the catalog against the current COFEPRIS classification rules was an unglamorous week that decided the budget. The line settled across Class I and Class II. Because class drives both the official fee per product and the documentation burden, a classification memo written against Edition 4 would have produced a plan costed against rules that no longer applied.

The map drawn before the first dossier

The next artifact was not a dossier. It was a grouping map.

COFEPRIS allows several products under one registration where manufacturer, commercial or distinctive name, indication or purpose of use, and technology or formulation align — the conditions are set out on the same classification page. For a reagent catalog sold in many presentations, that is the difference between registering a product line and registering every presentation of it separately, and it is the single largest lever on what the whole program costs.

The conditions are narrower than the word "family" suggests, which is where the manufacturer's original assumption had come from — and grouping is the one decision with an immediate penalty for getting wrong. An application containing devices that cannot be grouped is rejected, and the ineligible ones are refiled separately, paying the official fee again and restarting the clock. A rejection in the opening batch would not have cost only the opening batch; it would have put every assumption behind it in doubt. So the map came first, before a single page of technical file existed.

Two routes, decided product by product

Mexico offers two ways in, and the catalog used both. The detail for each sits on our COFEPRIS regulations page.

The standard route puts a full technical dossier through comprehensive COFEPRIS review, on timelines that vary with complexity and submission volume. The equivalency route — equivalencia, the abbreviated pathway — grants authorization on the strength of an approval already issued by a recognized reference authority, and it had recently become much more useful: under the Lineamientos published in the DOF on 18 July 2025 (applications opened that September), device eligibility rests on prior authorization from a regulator of a country on the IMDRF Management Committee — which is what qualifies approvals from FDA, the EU's CE regime, Health Canada, Swissmedic, ANVISA, TGA, MFDS and NMPA — with full MDSAP members additionally recognized for GMP certification. Under that route COFEPRIS is required to decide within 30 business days of receiving a complete application.

Holding FDA clearances and CE certificates, the manufacturer took the whole catalog to be on the abbreviated route. It put much of the line in reach, but eligibility had to be established one product at a time, because the route turns on identity: the device submitted must be identical to the version the reference authority approved — formulation, manufacturing process, intended use and technical specifications. "Substantially similar" is not a category the route recognizes, and a presentation that had drifted from its reference version did not qualify. Establishing that product by product was tedious in the mapping phase and would have been expensive at any later point. Products that qualified went the abbreviated way; the rest went standard.

The second condition shaped the work more than the first, and it corrected the assumption everyone starts with — that the clock begins when the file goes in. It begins when COFEPRIS receives a complete application. An incomplete file does not start it at all, and heavy submission volumes can push real decisions past the target regardless. On a catalog, that moves the constraint off the regulator's desk and onto the dossier, which is why the next decision was taken before anything was filed.

The label that had to be right the first time

Labeling had been scheduled the way most manufacturers schedule it: a translation task, near the end, once the technical work was done. It is not that in Mexico.

The rules sit in NOM-137-SSA1-2008 — still the standard in force: its successor, NOM-137-SSA1-2025, was published in May 2026 but does not take effect until 14 May 2027, with a further 180 days to exhaust existing packaging. Under the current NOM: Spanish required, trade name the only exception, and — the part that governs scheduling — the label design is submitted as part of the registration, with printed labels then required to match what was approved. So the template was built to the 2008 standard with the 2027 changeover already on the calendar. The full content requirements are set out on our COFEPRIS labeling page.

The asymmetry is what mattered here. Once a design is approved inside a registration, changing it requires a modification filing, and modifications can take several months to review. For a single product that is an irritation. For a catalog filed in batches over a year it is a scheduling hazard: a labeling convention discovered to be wrong in the autumn would have dragged every registration granted in the spring into a months-long queue behind it.

So the Spanish label template was over-engineered once, before the first submission, and then left alone — the same template carried through every later batch without reopening a granted file. One provision took pressure off the manufacturer's printing operation: the NOM permits import under the original manufacturer label where a compliant secondary label is applied that does not obscure required information or introduce conflicting claims. For a catalog already printed for other markets, that was a label-application step rather than a re-print program.

Around it, the rest of the file came together without much drama — a Certificate of Free Sale, the foreign approvals, technical and clinical documentation, a Letter of Representation appointing the MRH, distributor details, everything in Spanish. The quality evidence was the one place worth checking early: ISO 13485 is not legally mandatory in Mexico, but COFEPRIS expects robust quality-system evidence, and because the manufacturer held an MDSAP certificate — which Mexico recognizes as GMP evidence in place of a Mexican GMP inspection report — nothing new had to be commissioned.

March, a long quiet, then the autumn

The catalog did not go in all at once, and the reason was not caution.

A single mass submission replicates any systematic problem across every file before the first piece of feedback arrives. Filed in batches, whatever COFEPRIS surfaces on the opening group lands while the remaining dossiers are still open and can absorb it. The commercial argument pointed the same way: products cleared early can be imported and sold while the rest are still in preparation, so revenue does not wait for the last registration in the catalog.

The published register shows the shape that produced. An opening batch was granted in March. Then a quiet middle stretch, while the bulk of the catalog was mapped, drafted and labeled against the templates the first batch had proved. Then a continuous run from September through December, batch after batch appearing as consecutive blocks of grants.

What that year demonstrated is the part worth carrying into any Mexican plan: the expensive work is front-loaded and does not recur. The grouping map was built once. The dossier template was built once. The Spanish label template was built once and never reopened. The holder relationship was established once. Each later batch was mostly assembly against structures that already existed — which is why a first registration is a poor predictor of the cost of the ones after it, and why budgeting a catalog as repeated copies of the first overstates it. (Compiling and submitting an application runs 3–4 weeks once requirements are in hand — a market-level figure from our Mexico market page. Grant dates in a public register say as much about queue conditions as about any one dossier, so we do not publish review durations from our own filings.)

The licence nobody had budgeted for

The first registrations issued and the distributor prepared to order, on the reasonable understanding that a registration is permission to ship. It is not. A second permission was standing between the catalog and the border.

A sanitary registration authorizes sale; it does not by itself authorize import. A separate import licence is required, and licences run for up to 180 days or for a set quantity of devices, extendable once by an equal period. When the terms are exhausted, a new one has to be applied for, and that can take 3–4 weeks. For a catalog shipping in volume, the licence expires on a rhythm entirely unrelated to the registration it sits under.

This is the kind of obligation that is invisible until a shipment stops at customs. It was caught by the holder watching the terms and reapplying before they ran out, which is ordinary MRH work — but only where a holder is actually doing it, and precisely the sort of continuity that is nobody's clear job under a casual distributor-held arrangement. Alongside it, technovigilance began: NOM-240 requires a post-market surveillance and vigilance system — made a statutory duty outright by the January 2026 health-law reform — with the MRH primarily responsible for reporting incidents and adverse events to CENAFyT, the Centro Nacional de Farmacovigilancia y Tecnovigilancia that replaced the former CNFV under that same reform, though manufacturers and distributors are expected to report as well. Not every incident is reportable; events causing or capable of causing death, serious deterioration of health or a public-health threat are, on defined timelines. Both obligations are set out on our Mexico post-market compliance page.

The reform that improved the arithmetic

One rule changed in the program's favour while it ran — twice. Mexican registrations are initially valid for five years, and the extension calendar runs on a 150-natural-day filing window ahead of expiry. The first extension is the heavy one, requiring the application and fee, a Power of Attorney, a technovigilance report, a representation letter, and GMP certification or an equivalent such as an ISO 13485 certificate. Subsequent extensions need less paper and less processing.

Then the arithmetic improved. The January 2026 reform to the General Health Law set renewal terms at ten years, and the April 2026 reform to the health-supplies regulations extended that to both the first and subsequent extensions. For a catalog rather than a single product, that materially changes the long-run position: the five-year opening cycle carries the cost and the documentation, and each well-maintained registration is then held for a decade at a time. The technovigilance file that had been running since the first grants was, by then, also the evidence the first extension would require.

The outcome, and the bill

The registrations are in force, held by our Mexican entity as MRH, with the distributor selling underneath them and free to be replaced or joined by others without the authorizations moving. Import licences are tracked on their own clock, technovigilance runs continuously, and the renewal calendar is set against the 150-day filing window.

What a program shaped like this one costs, at the published rates:

COFEPRIS government fees (per product)

Government fees only, assessed per product. New-registration fees are one-time; renewal fees recur at the renewal cycle. Rates as published, last verified January 2026, subject to change without notice.

Our flat annual fee

The flat fee covers dossier preparation and submission, in-country representation as MRH, translation, modifications, adding or changing distributors on the registration, and post-market support; COFEPRIS and other government fees, certified translations and non-English source translations are separate. A three-year contract locks the rates; catalogs of 11+ are quoted individually.

Priced at those rates, two illustrative catalogs — modelled at the published fees, not descriptions of the registrations above:

A diagnostic-agent line of 8 Class I Low Risk products. Official fees: 8 × MXN 16,499 = MXN 131,992 (≈ USD 7,464), one-time. Service fee: USD 7,500/year covering all eight products plus the MRH role. First-year total ≈ USD 14,964, of which roughly half does not recur.

Five Class II diagnostic agents. Official fees: 5 × MXN 24,198 = MXN 120,990 (≈ USD 6,845), one-time. Service fee: USD 9,000/year. First-year total ≈ USD 15,845.

Price your own mix in the fee calculator.

Doing this for your product line

The order this engagement followed is the order that works: settle who holds the registro sanitario before anything is filed, re-run classification against the current Pharmacopoeia edition rather than trusting a memo written against an older one, draw the grouping map before the first dossier, establish equivalencia eligibility product by product instead of assuming your FDA or CE approval covers the line, over-engineer the Spanish label once so you never reopen a granted file, file in batches so the early ones teach the later ones, and treat import licences, technovigilance and the 150-day renewal window as part of the same engagement rather than as an afterthought.

If Mexico is one of several markets on your plan, the same structure runs market by market through global medical device registration — see how these decisions played out under ANVISA in our Brazil endoscope case study.

Start with the Mexico market page, or talk to our team about your catalog.